Effect of hazelnut consumption on lipid profile in diabetic patients

Effect of hazelnut consumption on lipid profile, Apo B, Apo A-I, hs-CRP and Paraoxonase-1 in patients with type 2 diabetes.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT138807262602N1

Enrollment

Registered

2009-12-02

Start date

2009-12-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes, Diabetic Dyslipidemia. Diabetes mellitus

Interventions

Intervention 1: Intervention: Hazelnut Consumption (10% of daily total calorie intake), 1 time/day, for 2 month. Intervention 2: Control: No intervention for this group.

Treatment - Other

Intervention: Hazelnut Consumption (10% of daily total calorie intake), 1 time/day, for 2 month

Control: No intervention for this group

Eligibility

Sex/Gender

All

Age

35 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Being volunteer or Wishing to attend, 35-70 y old, diagnosed with type 2 diabetes for at least 1 year (FPG = 126 mg/dl or 2hPG = 200 mg/dl), BMI = 35 kg/m2, TG 2 times/wk at least 2 months before the study, Changing medication dosage or physical activity level 2 mo before or during the study

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Decrease Total Cholesterol (TC). Timepoint: 8 weeks. Method of measurement: Friedewald equation.;Decrease Low Density Lipoprotein (LDL-C). Timepoint: 8 week. Method of measurement: Laboratory kit.;Decrease Triglyceride (TG). Timepoint: 8 weeks. Method of measurement: Laboratory Kit.;Increase High Density Lipoprotein (HDL-C). Timepoint: 8 weeks. Method of measurement: Laboratory kit.;Decrease TC/HDL-C ratio. Timepoint: 8 weeks. Method of measurement: calculation.;Decrease LDL-C/HDL-C ratio. Timepoint: 8 weeks. Method of measurement: Calculation.;Increase Apo A-I. Timepoint: 8 weeks. Method of measurement: immunoturbidimetry.;Decrease Apo B-100. Timepoint: 8 weeks. Method of measurement: immunoturbidimetry.;Increase Paraoxonase-1. Timepoint: 8 weeks. Method of measurement: spectrophotometry.;Decrease Fasting Blood Sugar (FBS). Timepoint: 8 weeks. Method of measurement: Enzymatic.;Decrease Fasting Insulin. Timepoint: 8 weeks. Method of measurement: Enzymatic.;Increase Total Antioxidant Capacity (TAC). Timepoint: 8 weeks. Method of measurement: Ferric reducing ability of plasma (FRAP).;Decrease high sensitivity C-reactive protein (hs-CRP). Timepoint: 8 weeks. Method of measurement: Immunoturbidimetry.;Decrease blood pressure. Timepoint: 8 weeks. Method of measurement: sphygmomanometer.	—

Measure

Time frame

Decrease Total Cholesterol (TC). Timepoint: 8 weeks. Method of measurement: Friedewald equation.;Decrease Low Density Lipoprotein (LDL-C). Timepoint: 8 week. Method of measurement: Laboratory kit.;Decrease Triglyceride (TG). Timepoint: 8 weeks. Method of measurement: Laboratory Kit.;Increase High Density Lipoprotein (HDL-C). Timepoint: 8 weeks. Method of measurement: Laboratory kit.;Decrease TC/HDL-C ratio. Timepoint: 8 weeks. Method of measurement: calculation.;Decrease LDL-C/HDL-C ratio. Timepoint: 8 weeks. Method of measurement: Calculation.;Increase Apo A-I. Timepoint: 8 weeks. Method of measurement: immunoturbidimetry.;Decrease Apo B-100. Timepoint: 8 weeks. Method of measurement: immunoturbidimetry.;Increase Paraoxonase-1. Timepoint: 8 weeks. Method of measurement: spectrophotometry.;Decrease Fasting Blood Sugar (FBS). Timepoint: 8 weeks. Method of measurement: Enzymatic.;Decrease Fasting Insulin. Timepoint: 8 weeks. Method of measurement: Enzymatic.;Increase Total Antioxidant Capacity (TAC). Timepoint: 8 weeks. Method of measurement: Ferric reducing ability of plasma (FRAP).;Decrease high sensitivity C-reactive protein (hs-CRP). Timepoint: 8 weeks. Method of measurement: Immunoturbidimetry.;Decrease blood pressure. Timepoint: 8 weeks. Method of measurement: sphygmomanometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Shahriar Eghtesadi

School of Health, Iran University of Medical Sciences

egtesadi@iums.ac.ir, egtesadi@yahoo.com+98 21 8877 9118

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026